Paper
0
MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
Authors
Pieter Sonneveld,Philippe Moreau
Meletios Dimopoulos,Hang Quach,P. Ho,Meral Beksaç,Cyrille Hulin,Elisabetta Antonioli,Xavier Leleu,Silvia Mangiacavalli,Aurore Perrot,Michèle Cavo,Angelo Belotti,Annemiek Broijl,Francesca Gay,Roberto Mina,Inger Nijhof,Niels Donk,Eirini Katodritou,Fredrik Schjesvold,Anna Sureda,Laura Rosiñol,Michel Cavo,Wilfried Roeloffzen,Christoph Driessen,Annette Vangsted,Hermann Einsele,Andrew Spencer,Roman Hájek,Artur Jurczyszyn,Sarah Lonergan,Yanfang Liu,Jianping Wang,Diego Vieyra,Emilie Brummelen,Véronique Vanquickelberghe,Carla Boer,Richard Carson,Joan Bladé,Mario Boccadoro
+38 authors
,Paula Rodríguez‐OteroPublished
Sep 1, 2024
Show more
Save
Tip0
TipSave